Nightstar Therapeutics was an Oxford University spinout developing adeno-associated virus (AAV) gene therapies for inherited retinal diseases including choroideremia and retinitis pigmentosa. Founded in 2014, it completed a NASDAQ IPO in 2017 and was acquired by Biogen for approximately $800 million in June 2019.
Create a free account to see funding visualizations and detailed round data.
Create Free AccountCreate a free account to see full funding history, valuations, and investor participation.
Create Free AccountCreate a free account to see which investors have funded this company.
Create Free Account